You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In PLOS this week: links between placental transcriptome and weight; colorectal cancer-related microRNAs; and more.
Researchers are developing blood tests to determine people's chronotypes, according to Scientific American.
In Genome Biology this week: catalog of curated human genes and transcripts; potential biomarkers for aging; and more.
The finding could help detect autologous blood doping among athletes, Dark Daily reports.
The company beat the consensus Wall Street estimate on the top line and guided to 2018 revenues of between $21 million and $22 million.
In adults and children with Crohn's, miR-31 was found at higher levels in gut tissue, and the cases marked by lower expression tended to have poorer outcomes.
The blood-based test, called Melaseq, measures 38 circulating microRNAs that regulate processes that melanoma cells undergo as they become malignant.
The company said the NIH funding will enable it to further validate the saliva-based test and prepare it for commercial launch later this year.
Priorities for Q3 include the continued buildup of a commercial launch for the company's BarreGEN test. The firm has started a second clinical validation study for the test.
In PLOS this week: mutation linked to progressive ataxia in Charolais cattle, microRNA expression levels linked to colorectal cancer, and more.
Nearly 30,000 COVID-19 tests the UK sent to the US came back as void, according to the Telegraph.
Black principal investigators receive less favorable application scores when seeking US National Institutes of Health grants, the Chronicle of Higher Education reports.
New Scientist reports that both RNA and DNA may have been involved in the emergence of life on Earth.
In Nature this week: new Sperm-seq method enables crossover analysis, tumor-informed detection approach for minimal residual disease, and more.